News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
677,362 Results
Type
Article (38746)
Company Profile (245)
Press Release (638371)
Section
Business (203312)
Career Advice (1975)
Deals (35346)
Drug Delivery (77)
Drug Development (80547)
Employer Resources (167)
FDA (15973)
Job Trends (14771)
News (343345)
Policy (32402)
Tag
Academia (2531)
Africa (710)
Alliances (48934)
Alzheimer's disease (1132)
Approvals (15922)
Arizona (169)
Artificial intelligence (64)
Asia (36709)
Australia (5969)
Bankruptcy (351)
Best Places to Work (11206)
Biosimilars (60)
Biotechnology (170)
C2C Services and Suppliers (78832)
California (1477)
Canada (819)
Cancer (312)
Career advice (1645)
Cell therapy (94)
China (105)
Clinical research (62896)
Collaboration (99)
Colorado (62)
Connecticut (58)
COVID-19 (2470)
Cystic fibrosis (71)
Data (117)
Diabetes (64)
Diagnostics (5937)
Drug pricing (57)
Earnings (83604)
Employer resources (140)
Europe (78448)
Events (107264)
Executive appointments (86)
FDA (16135)
Florida (204)
Funding (87)
Gene therapy (73)
GLP-1 (495)
Government (4280)
Healthcare (18562)
Hotbed/Location (481024)
Idaho (56)
Illinois (230)
Indiana (131)
Infectious disease (2494)
Inflammatory bowel disease (86)
Interviews (305)
IPO (16164)
Job creations (3618)
Job search strategy (1412)
Kansas (93)
Layoffs (387)
Legal (7827)
Liver cancer (54)
Lung cancer (66)
Manufacturing (70)
Maryland (332)
Massachusetts (1249)
Medical device (13008)
Medtech (13011)
Mergers & acquisitions (18984)
Metabolic disorders (211)
Michigan (112)
Minnesota (199)
Neuroscience (1241)
New Jersey (461)
New York (471)
NextGen Class of 2024 (6478)
Non-profit (4453)
North Carolina (552)
Northern California (672)
Obesity (130)
Ohio (96)
Opinion (167)
Pennsylvania (507)
People (55694)
Pharmaceutical (59)
Phase I (19488)
Phase II (27709)
Phase III (20698)
Pipeline (86)
Postmarket research (2547)
Preclinical (8295)
Press Release (64)
Rare diseases (110)
Real estate (5877)
Recruiting (63)
Regulatory (21123)
Research institute (2301)
Resumes & cover letters (345)
South America (1084)
Southern California (602)
Startups (3554)
Texas (176)
United States (7152)
Vaccines (442)
Washington State (228)
Weight loss (114)
Date
Today (120)
Last 7 days (441)
Last 30 days (2499)
Last 365 days (37636)
2024 (24289)
2023 (40085)
2022 (51186)
2021 (55715)
2020 (54087)
2019 (46553)
2018 (35023)
2017 (32118)
2016 (31492)
2015 (37560)
2014 (31329)
2013 (26364)
2012 (28583)
2011 (29283)
2010 (27344)
677,362 Results for "clene nanomedicine inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Clene to Present at Upcoming May 2024 Conferences
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, announced that it will participate in the following investor conferences in May.
May 14, 2024
·
1 min read
Clene to Present at the Emerging Growth Conference
Clene Inc. today announced that management will present at the Emerging Growth Conference.
June 5, 2024
·
2 min read
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc. today announced several key updates on its National Institutes of Health (NIH)-funded Accelerating Access to Critical Therapies Expanded Access Program (ACT-EAP) for CNM-Au8® compassionate use in ALS.
May 28, 2024
·
8 min read
Business
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis and multiple sclerosis, announced its first quarter 2024 financial results and provided recent operating highlights for the CNM-Au8 clinical program for MS.
May 8, 2024
·
12 min read
BioMidwest
Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc. presented new long-term CNM-Au8 treatment results for survival and neurofilament light levels from the HEALEY ALS Platform Trial open label extension at the European Network for the Cure of ALS meeting in Stockholm, Sweden.
June 18, 2024
·
6 min read
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
Clene Inc. today announced it presented new, preliminary data demonstrating the potential of CNM-Au8 as a treatment for Rett Syndrome.
June 21, 2024
·
8 min read
Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference
Clene Inc. today announced that management will present at H.C. Wainwright’s 5th Annual Neuro Perspective Virtual Conference and host 1x1 investor meetings.
June 24, 2024
·
1 min read
Business
Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights
Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. today announced its full year 2023 financial results and provided recent operating highlights for the clinical programs in ALS and MS.
March 13, 2024
·
16 min read
BioMidwest
Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs
Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including ALS and multiple sclerosis, reported new, significant survival results from two independent analyses of the pooled data from the intermediate-size EAPs supported by Clene.
February 22, 2024
·
9 min read
Clene to Present at the 36th Annual ROTH Conference
Clene Inc. today announced that it will participate in the 36th Annual ROTH Conference being held March 18-19, 2024.
March 7, 2024
·
1 min read
1 of 67,737
Next